Agomab Therapeutics NV is a Belgium-based biotech company. The Company is engaged in the development of antibodies for damaged tissues. It develops novel treatments that aim to preserve and restore organ function in fibrotic diseases. It also develops growth factor-mimetic agonistic monoclonal antibodies to regenerate damaged tissues. The Company targets growth factors and modulates related molecular pathways through monoclonal antibodies and small molecule compounds to resolve fibrosis, regenerate tissue and restore organ functionality. It works with academic institutions and industrial partners to develop treatment options for patients.
BörsenkürzelAGMB
Name des UnternehmensAgomab Therapeutics NV
IPO-datum- -
CEO- -
Anzahl der mitarbeiter- -
WertpapierartDepository Receipt
Geschäftsjahresende- -
AddressePosthoflei 1 box 6
Stadt
BörseNASDAQ OMX - NASDAQ BASIC
LandBelgium
Postleitzahl2600
Telefon
Website
BörsenkürzelAGMB
IPO-datum- -
CEO- -
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.

Keine Daten